Manulife (Manufacturers Life Insurance)
ITCI

Manulife (Manufacturers Life Insurance)’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,085
Closed -$935K – 3032
2025
Q1 		$935K Sell
7,085
-14,604
-67% -$1.82M ﹤0.01% 1840
2024
Q4 		$1.81M Sell
21,689
-368
-2% -$30.2K ﹤0.01% 1609
2024
Q3 		$1.61M Buy
22,057
+283
+1% +$21.3K ﹤0.01% 1663
2024
Q2 		$1.49M Sell
21,774
-31,267
-59% -$2.17M ﹤0.01% 1615
2024
Q1 		$3.67M Sell
53,041
-26,701
-33% -$1.84M ﹤0.01% 1306
2023
Q4 		$5.71M Buy
79,742
+26,108
+49% +$1.5M ﹤0.01% 1103
2023
Q3 		$2.79M Buy
53,634
+15,753
+42% +$918K ﹤0.01% 1334
2023
Q2 		$2.4M Buy
37,881
+952
+3% +$59.3K ﹤0.01% 1357
2023
Q1 		$2M Buy
36,929
+133
+0.4% +$6.43K ﹤0.01% 1402
2022
Q4 		$1.95M Buy
36,796
+753
+2% +$37.7K ﹤0.01% 1387
2022
Q3 		$1.68M Sell
36,043
-611
-2% -$31.9K ﹤0.01% 1427
2022
Q2 		$2.09M Buy
36,654
+3,984
+12% +$226K ﹤0.01% 1409
2022
Q1 		$2M Sell
32,670
-1,749
-5% -$90.8K ﹤0.01% 1507
2021
Q4 		$1.8K Sell
34,419
-421
-1% -$17.7K ﹤0.01% 1544
2021
Q3 		$1.3M Sell
34,840
-3,472
-9% -$121K ﹤0.01% 1676
2021
Q2 		$1.56M Buy
38,312
+2,322
+6% +$85.8K ﹤0.01% 1722
2021
Q1 		$1.22M Sell
35,990
-2,442
-6% -$84.7K ﹤0.01% 1784
2020
Q4 		$1.22M Buy
38,432
+2,314
+6% +$60.8K ﹤0.01% 1715
2020
Q3 		$927K Buy
36,118
+4,475
+14% +$102K ﹤0.01% 1696
2020
Q2 		$797K Buy
31,643
+286
+0.9% +$5.79K ﹤0.01% 1727
2020
Q1 		$482K Buy
31,357
+5,209
+20% +$113K ﹤0.01% 1860
2019
Q4 		$897K Sell
26,148
-1,470
-5% -$17.6K ﹤0.01% 1732
2019
Q3 		$207K Hold
27,618
– – ﹤0.01% 2565
2019
Q2 		$358K Sell
27,618
-1,274
-4% -$16.3K ﹤0.01% 2256
2019
Q1 		$352K Buy
28,892
+1,082
+4% +$13.8K ﹤0.01% 2211
2018
Q4 		$317K Sell
27,810
-690
-2% -$11.1K ﹤0.01% 2151
2018
Q3 		$619K Sell
28,500
-3,886
-12% -$81.3K ﹤0.01% 2126
2018
Q2 		$572K Buy
32,386
+1,888
+6% +$38.3K ﹤0.01% 2279
2018
Q1 		$642K Sell
30,498
-1,122
-4% -$21.9K ﹤0.01% 2148
2017
Q4 		$458K Buy
31,620
+6,274
+25% +$96.9K ﹤0.01% 2378
2017
Q3 		$400K Sell
25,346
-858
-3% -$12.6K ﹤0.01% 2438
2017
Q2 		$325K Sell
26,204
-881
-3% -$10.2K ﹤0.01% 2634
2017
Q1 		$440K Buy
27,085
+3,652
+16% +$52.9K ﹤0.01% 2293
2016
Q4 		$353K Buy
23,433
+961
+4% +$13.6K ﹤0.01% 2352
2016
Q3 		$342K Buy
22,472
+55
+0.2% +$2.22K ﹤0.01% 2364
2016
Q2 		$870K Buy
22,417
+5,701
+34% +$205K ﹤0.01% 1703
2016
Q1 		$463K Buy
16,716
+2,958
+22% +$98.6K ﹤0.01% 2018
2015
Q4 		$740 Buy
13,758
+104
+0.8% +$5.25K ﹤0.01% 1781
2015
Q3 		$546 Buy
13,654
+366
+3% +$11.9K ﹤0.01% 1939
2015
Q2 		$425 Buy
13,288
+2,489
+23% +$63.1K ﹤0.01% 2244
2015
Q1 		$258 Sell
10,799
-139
-1% -$3.11K ﹤0.01% 2541
2014
Q4 		$193 Hold
10,938
– – ﹤0.01% 2673
2014
Q3 		$150 Buy
10,938
+176
+2% +$2.64K ﹤0.01% 2832
2014
Q2 		$182K Buy
+10,762
New +$178K ﹤0.01% 2788

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s ITCI Position: Q2 2025 in Review

Manulife (Manufacturers Life Insurance) sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 7,085 shares — an estimated $935K sold.

Manulife (Manufacturers Life Insurance) first reported a position in ITCI in Q2 2014 and held it in 44 quarters. The position peaked at $5.71M in Q4 2023. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Manulife (Manufacturers Life Insurance) reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 7,085 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $935K.
  • Manulife (Manufacturers Life Insurance) first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and held it in 44 quarters.
  • Manulife (Manufacturers Life Insurance)'s Intra-Cellular Therapies Inc. position peaked at $5.71M in Q4 2023.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2025, filed 14 Aug 2025.